Size-adjusted muscle power and muscle metabolism in patients with cystic fibrosis are equal to healthy controls – a case control study

Table 1 Participants’ characteristics/results of lung function and exercise testing

	Patients with CF (n = 20)	Healthy controls (n = 23)
Female (n/[%])	6 [30]	10 [43]
Anthropometric data
Age (years)	21.7 ± 8 (12–42)	21.2 ± 6 (15–43)
Height (cm)	164.4 ± 12.0 (138–185)	174.5 ± 7.5 (160–192) ^***
Weight (kg)	56.6 ± 13.9 (31–79)	67.8 ± 8.7 (52–94) ^***
Lung function
FEV₁ (%pred)	74.3 ± 20.4 (25.7–103.0)	103.3 ± 12.2 (77.2–123.6) ^***
FVC (%pred)	91.2 ± 17.0 (41.4–96.4)	101.0 ± 10.3 (77.2–125-8) ^*
RV%TLC	30.7 ± 13 (23.7–41.8)	22.9 ± 4 ^* (19.3–31.3)
TLCO%	86.7 ± 17.4 (47.8–112.5)	94.4 ± 17.6 (67.8–128.0)
Incremental cycling exercise test (Godfrey protocol)
VO₂ peak (%pred)	77.8 ± 16.2 (44.3–110.1)	100.6 ± 18.8 (60.1–136-0) ^***
VO₂peak/qCSA ml/min	36.5 ± 7.4 (23.4–53.1)	49.1 ± 11.4 (23.5–77.7) ^***
RER	1.17 ± 0.1 (0.9–1.4)	1.21 ± 0.1 (1.1–1.4)
Peak heart rate (bpm)	171 ± 15.4 (140–201)	183 ± 9.8 (166–202) ^**
SPO₂ peak exercise (%)	96 ± 2.6 (90–100)	98 ± 2.1 (91–100) ^*

All parameters are reported as mean ± standard deviation (range); differences between participants with and without CF were calculated using Student’s t-test. Significant data is marked by ^***p < 0.001, ^** p < 0.01, ^* p < 0.05

ISSN: 1471-2466